Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Autor: Novello, Silvia, Kaiser, Rolf, Mellemgaard, Anders, Douillard, Jean-Yves, Orlov, Sergey, Krzakowski, Maciej, von Pawel, Joachim, Gottfried, Maya, Bondarenko, Igor, Liao, Meilin, Barrueco, José, Gaschler-Markefski, Birgit, Griebsch, Ingolf, Palmer, Michael, Reck, Martin
Zdroj: In European Journal of Cancer February 2015 51(3):317-326
Databáze: ScienceDirect
Externí odkaz: